FMP
Eton Pharmaceuticals, Inc.
ETON
NASDAQ
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
12.45 USD
0.48 (3.86%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
429.9M
518.16M
629.1M
728.94M
786.57M
915.79M
1.07B
1.24B
1.45B
1.68B
Revenue %
-
20.53
21.41
15.87
7.91
16.43
16.43
16.43
16.43
Ebitda
-62.27M
-63.53M
-129.97M
-78.53M
-89.33M
-127.36M
-148.29M
-172.65M
-201.01M
-234.04M
Ebitda %
-14.48
-12.26
-20.66
-10.77
-11.36
-13.91
-13.91
-13.91
-13.91
Ebit
-73.33M
-78.83M
-157.4M
-103.12M
-89.26M
-151.62M
-176.54M
-205.54M
-239.31M
-278.62M
Ebit %
-17.06
-15.21
-25.02
-14.15
-11.35
-16.56
-16.56
-16.56
-16.56
Depreciation
11.05M
15.3M
27.42M
24.59M
-69k
24.26M
28.25M
32.89M
38.29M
44.58M
Depreciation %
2.57
2.95
4.36
3.37
-0.01
2.65
2.65
2.65
2.65
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
